secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001517022-23-000042
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Q3 net loss $14.5M, Auryxia rev $40.1M, vadadustat PDUFA Mar 27, 2024
----------------------------------------------------------------------------

- Net loss improved to $14.5M from $54.1M in Q3 2022; total revenue $42.0M, down from $48.7M.
- Auryxia net product revenue $40.1M (Q3 2022: $42.0M); FY 2023 guidance reaffirmed at $170-175M.
- Vadadustat NDA resubmission accepted; PDUFA date set for March 27, 2024 for anemia in dialysis CKD.
- Vadadustat approved in 36 countries including Australia and Taiwan; five posters at Kidney Week 2023.
- Modified Pharmakon loan: principal payments deferred to Oct 2024, maturity extended to March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000042/0001517022-23-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000042/akba-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001517022-23-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer